by ElasmoAdm1n | Jan 6, 2026 | News Archive
Novel soloMER based albumin binder will be used for two therapeutic fusion proteinsâ„¢ Aberdeen, Scotland and Seoul, Korea; January 7th 2019:Â Elasmogen Ltd, developer of next generation soloMER biologics, announced today that ImmunoForge has entered a license agreement...
by ElasmoAdm1n | Jan 6, 2026 | News Archive
Life Sciences Scotland have interviewed Elasmogen’s CEO Caroline Barelle as part of their Insight series. The article can be accessed here.
by ElasmoAdm1n | Jan 6, 2026 | News Archive
Craigavon, N.I., UK, 20 Mar 2019 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen a biotech company developing next generation therapeutic biologics, today...
by ElasmoAdm1n | Jan 6, 2026 | News Archive
Elasmogen is delighted to announce that shortlisted finalists for the 2019 BBSRC Innovator of the Year award include our CEO, Dr Caroline Barelle. The BBSRC Innovator of the Year award recognises the full breadth of impacts that BBSRC investments in research have...
by ElasmoAdm1n | Jan 6, 2026 | News Archive
Biotech media outlet Labiotech.eu which covers the European Biotech industry, has today, 21 May 2019, listed Elasmogen CEO, Dr Caroline Barelle among top 20 women in leading biotech roles in Europe. The full article can be found...
by ElasmoAdm1n | Jan 6, 2026 | News Archive
Elasmogen’s CEO Dr Caroline Barelle has been featured in Insight Success special edition Successful Women Making a Difference in Biotech. The article can be read here. Dr. Caroline Barelle: A Leader in Biotechnology Driving Innovation in Biologics Drug...